Comparison 1. Live zoster vaccine versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of herpes zoster	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 3.1 years follow‐up	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 30 days of vaccination	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 42 days of vaccination	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.4 3.3 to 7.8 years after vaccination substudy	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.5 Mean 5 years follow‐up	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Interference of herpes zoster in activities of daily life	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3 Participants with adverse events	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Death	5	50820	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.92, 1.11]
3.2 1 or more serious adverse events regardless of type of storage of the vaccine	6	51029	Risk Ratio (M‐H, Random, 95% CI)	1.08 [0.95, 1.21]
3.3 Vaccine‐related serious adverse events	4	50766	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.24, 4.15]
3.4 Hospitalised	1	6616	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.93, 1.07]
3.5 Hospitalisation related to herpes zoster	1	6616	Risk Ratio (M‐H, Random, 95% CI)	0.81 [0.25, 2.67]
3.6 1 or more adverse events	5	7119	Risk Ratio (M‐H, Random, 95% CI)	1.71 [1.38, 2.11]
3.7 Vaccine‐related adverse events	3	342	Risk Ratio (M‐H, Random, 95% CI)	2.64 [1.21, 5.75]
3.8 Systemic adverse events	5	7119	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.82, 1.87]
3.9 Vaccine‐related systemic adverse events	3	6856	Risk Ratio (M‐H, Random, 95% CI)	1.30 [1.07, 1.58]
3.10 Systemic pruritus	2	263	Risk Ratio (M‐H, Random, 95% CI)	1.61 [0.12, 22.42]
3.11 General malaise	1	54	Risk Ratio (M‐H, Random, 95% CI)	1.0 [0.07, 15.18]
3.12 Headache	1	78	Risk Ratio (M‐H, Random, 95% CI)	1.0 [0.15, 6.75]
3.13 Varicella‐like rash not at injection site (day of vaccination to day 42)	3	38833	Risk Ratio (M‐H, Random, 95% CI)	1.10 [0.57, 2.11]
3.14 Rash unrelated to herpes zoster (day of vaccination to day 42)	2	38624	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.80, 1.18]
3.15 Injection site adverse events	4	7040	Risk Ratio (M‐H, Random, 95% CI)	3.73 [1.93, 7.21]
3.16 Erythema inoculation site	4	6958	Risk Ratio (M‐H, Random, 95% CI)	4.30 [2.66, 6.94]
3.17 Pain inoculation site	4	6958	Risk Ratio (M‐H, Random, 95% CI)	6.47 [2.67, 15.68]
3.18 Pruritus inoculation site	4	6958	Risk Ratio (M‐H, Random, 95% CI)	4.32 [1.49, 12.48]
3.19 Swelling inoculation site	3	6879	Risk Ratio (M‐H, Random, 95% CI)	5.84 [4.95, 6.89]
3.20 Warmth inoculation site	3	6879	Risk Ratio (M‐H, Random, 95% CI)	4.73 [2.57, 8.74]
3.21 Rash inoculation site	1	6616	Risk Ratio (M‐H, Random, 95% CI)	3.26 [1.31, 8.11]
3.22 Haematoma inoculation site	1	6616	Risk Ratio (M‐H, Random, 95% CI)	1.13 [0.76, 1.67]
3.23 Mass inoculation or induration site	2	6695	Risk Ratio (M‐H, Random, 95% CI)	7.05 [1.91, 26.05]
3.24 Varicella‐like rash at injection site (day of vaccination to day 42)	1	38546	Risk Ratio (M‐H, Random, 95% CI)	2.86 [1.21, 6.76]
3.25 Vaccine‐unrelated adverse event	1	54	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.12, 3.68]
3.26 Herpes zoster‐like rash (day of vaccination to day 42)	1	38546	Risk Ratio (M‐H, Random, 95% CI)	0.47 [0.27, 0.84]
4 Duration in days of adverse effects	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
4.1 Erythema	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 Pain	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Pruritus	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4.4 Swelling	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4.5 Rash	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4.6 Haematoma	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
5 Dropouts	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 For any reason	3	38916	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.91, 1.08]
5.2 Discontinued due to vaccine‐related adverse events	2	370	Risk Ratio (M‐H, Random, 95% CI)	5.05 [0.25, 103.88]
5.3 Clinical adverse event	2	12189	Risk Ratio (M‐H, Random, 95% CI)	1.34 [0.72, 2.52]
5.4 Physician decision	1	11980	Risk Ratio (M‐H, Random, 95% CI)	0.20 [0.01, 4.17]
5.5 Withdrew consent	4	50814	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.54, 1.68]
5.6 Lost to follow‐up	5	50868	Risk Ratio (M‐H, Random, 95% CI)	1.27 [0.96, 1.69]
5.7 Protocol deviation	2	12189	Risk Ratio (M‐H, Random, 95% CI)	1.49 [0.27, 8.37]
6 Participants with no follow‐up	3	50627	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.41, 1.74]